Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle Sells 5,177 Shares

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 5,177 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $23.15, for a total transaction of $119,847.55. Following the sale, the chief financial officer owned 167,732 shares in the company, valued at approximately $3,882,995.80. This represents a 2.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

David Mountcastle also recently made the following trade(s):

• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The shares were sold at an average price of $22.84, for a total transaction of $133,134.36.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total transaction of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The stock was sold at an average price of $25.05, for a total transaction of $192,809.85.
• On Friday, December 12th, David Mountcastle sold 23,887 shares of Privia Health Group stock. The shares were sold at an average price of $25.03, for a total value of $597,891.61.

Privia Health Group Stock Down 3.6%

Shares of Privia Health Group stock opened at $22.47 on Wednesday. Privia Health Group, Inc. has a twelve month low of $18.77 and a twelve month high of $26.51. The business has a 50-day moving average price of $23.00 and a 200 day moving average price of $23.61. The firm has a market cap of $2.78 billion, a PE ratio of 132.18, a P/E/G ratio of 1.52 and a beta of 0.82.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.21. The company had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.During the same quarter in the prior year, the firm posted $0.21 EPS. Privia Health Group’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, sell-side analysts expect that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Institutional Trading of Privia Health Group

Several large investors have recently bought and sold shares of PRVA. Great Lakes Advisors LLC purchased a new position in Privia Health Group in the 3rd quarter worth approximately $4,487,000. Advantage Alpha Capital Partners LP purchased a new stake in shares of Privia Health Group in the second quarter valued at approximately $3,941,000. Hsbc Holdings PLC increased its holdings in shares of Privia Health Group by 69.2% in the second quarter. Hsbc Holdings PLC now owns 113,718 shares of the company’s stock valued at $2,549,000 after purchasing an additional 46,526 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in shares of Privia Health Group in the second quarter valued at approximately $2,209,000. Finally, Bailard Inc. purchased a new position in Privia Health Group during the second quarter worth approximately $531,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Analyst Upgrades and Downgrades

PRVA has been the subject of several recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Privia Health Group in a report on Monday, December 29th. Piper Sandler reaffirmed an “overweight” rating and issued a $36.00 price target on shares of Privia Health Group in a research note on Thursday, February 26th. Jefferies Financial Group reiterated a “buy” rating and issued a $32.00 price objective on shares of Privia Health Group in a report on Thursday, February 26th. Citigroup cut their price objective on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Finally, Canaccord Genuity Group increased their target price on Privia Health Group from $34.00 to $35.00 and gave the company a “buy” rating in a report on Friday, February 27th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Privia Health Group has an average rating of “Moderate Buy” and an average target price of $31.00.

Privia Health Group News Roundup

Here are the key news stories impacting Privia Health Group this week:

• Negative Sentiment: CEO Parth Mehrotra sold 21,440 shares on March 6 at $23.15 and 41,999 shares on March 9 at $22.86 (total ≈63,439 shares, ≈$1.46M). His holdings fell to 343,795 shares after the sales. CEO Form 4
• Negative Sentiment: CFO David Mountcastle completed two sales (5,177 shares on March 6 at $23.15 and 5,829 shares on March 9 at $22.84), totaling 11,006 shares (~$253k) and reducing his stake to ~161,903 shares. CFO Form 4
• Negative Sentiment: EVP Edward C. Fargis sold 4,394 shares on March 6 at $23.15 and 4,949 shares on March 9 at $22.84 (total 9,343 shares, ~ $215k), lowering his holding to ~83,711 shares. EVP Form 4

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.